INCLINE VILLAGE, Nev., /PRNewswire/ — PDL BioPharma, Inc. (NASDAQ: PDLI) (PDL or the Company) today announced that PDL has received approximately in connection with the termination of PDL’s credit agreement with Paradigm Spine, LLC, which included a repayment of the full principal amount outstanding of as well as accrued interest and a prepayment fee. In , PDL entered into a credit agreement with Paradigm Spine in which it made available up to of debt financing with a five-year term, and initially provided , net of fees. PDL subsequently provided an additional in as part of an amendment to the credit agreement.
About PDL BioPharma, Inc.
PDL seeks to acquire pharmaceutical products through equity investments and also provide growth capital and financing solutions to late-stage public and private healthcare companies, including immediate financial monetization of royalty streams to companies, academic institutions, and inventors. PDL has committed over and funded approximately in these investments to date. PDL evaluates its investments based on the quality of the income generating assets and potential returns on investment. PDL is currently focused on acquiring and managing income generating assets, and maximizing value for its stockholders.
The Company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL was founded in 1986 and is headquartered in . PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases for which it receives significant royalty revenue.
PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.